Since it started selling its all-electric roadster more than a decade ago, Tesla has dominated the electric vehicle (EV) market. The firm has seen exponential growth over the years, eventually gaining a market valuation of more than $300 billion. But while investors have been salivating for Tesla stock for a while now, other EV makers have not been so lucky. In fact, players in the young EV industry have had a relatively hard time securing capital.

Take Steve Burns, for instance. Although his company, Lordstown Motors, has already designed an electric truck, acquired a plant and machinery from General Motors, and racked up thousands of orders, he struggled to raise capital. However, like several other EV makers, he has found an alternative way to raise revenue. Last month, Lordstown Motors merged with a special purpose acquisition company (SPAC), a move that will snag the EV maker $675 million in capital and a listing on Nasdaq.

And unlike a traditional initial public offering (IPO), which can be a lengthy process, a SPAC merger takes only a couple of months. “The traditional IPO time is maybe a year and a half,” says Burns. “We are in a race to be the first with electric trucks. We want to get it done and get to the business of building the vehicle.”

Sometimes called blank-check companies, SPACs provide small or economically distressed firms with capital and the ability to list their shares on a stock exchange. They raise money from investors without having a dedicated business plan and then find a business to buy within two years. If that fails, the company folds, and the funds are returned to the original investors. The past few years have seen increased interest by SPAC investors in the electric vehicle industry, especially as more governments look toward net-zero economies.

Back in June, EV maker Nikola, which anticipates making heavy trucks powered by hydrogen fuel cells and electricity, also merged with a SPAC. Although Nikola hasn’t even started official production, investors have set its valuation at around $15 billion, more than half of Ford Motor’s valuation. According to SPACInsider, this year’s SPAC activity by dollar volume has almost doubled from all of last year, setting a record of $31.3 billion.

The EV industry still isn’t a sure thing, and given the current economic climate, investors have been wary of investing in EV makers. Boon Sim, the founder and managing partner of Artius Capital Partners, surmises it perfectly: “It’s always challenging to do a big IPO above $1 billion, especially in today’s volatile environment and the time it takes to file and tell your story to investors.”

One company worth watching in this space is Net Element (NASDAQ: NETE). NETE is a global financial solutions company that recently announced an agreement to merge with a California-based privately held electric vehicle company. Once that deal is completed, all eyes will be on the new company fares in the EV industry.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• Investment bank UBS reports that electric cars will cost the same to make as conventional cars by 2024.
• Expensive batteries, which account for between a quarter and two-fifths of EV’s cost, have been barrier to production.
• NETE recently announced entry into EV space through merger with privately held Mullen Technologies Inc.

New research from investment bank UBS indicates that electric vehicles (“EVs”) may be as cheap to manufacture as regular models within the next four years (https://ibn.fm/UV8WX). This news bodes well for Net Element Inc. (NASDAQ: NETE), a global financial technology and value-added solutions group that recently announced its planned entry into the EV space through an upcoming merger with privately held Mullen Technologies Inc. (https://ibn.fm/xBu5G).

According to the research, “electric cars will cost the same to make as conventional cars, with internal combustion engines, by 2024 and an acceleration in the shift away from fossil fuel vehicles may be imminent.” In addition, “the extra cost of manufacturing battery electric cars versus their fossil fuel equivalents will diminish to just $1,900 (£1,470) per car by 2022, and disappear completely by 2024, according to research by the investment bank UBS.”

This is big news to many car manufacturers, which have been “reluctant to shift production away from their profitable internal combustion engine models towards electric cars because of expensive batteries, which are almost exclusively made by east Asian companies. . . .  Batteries account for between a quarter and two-fifths of the cost of the entire vehicle.” UBS said it anticipates battery costs to drop below $100 per kilowatt hour (“kWh”), a key milestone, by 2022.

Mullen recently announced its own plans to start work on a manufacturing facility as well as accept pre-orders for its M05 fully electric SUV (https://ibn.fm/TKhPz). “We are excited to begin the build-out of our pilot facility and pre-sales of our MX-05 SUV in October,” said Mullen Technologies chairman and CEO David Michery. “We plan on completing the build-out by April 2021 and to begin assembly of certification prototypes by July 2021. These vehicles will be used for homologation, which is expected to take 16 months and be completed by May of 2022, at which time we expect to begin delivering the first vehicles to the public.”

The planned manufacturing facility, which was originally Mullen’s high-voltage battery R&D center, will be renovated to include general assembly as well as battery assembly capabilities; the structure will also house R&D and serve as a warehouse. When complete, the facility will be capable of producing up to 1,000 MX-05 EVs per year. In addition, the plant will manufacture other Mullen models, including the already announced MX-07 and MX-03.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution.

Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017 Net Element was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies.

For more information on Net Element, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses
• A planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) is expected to be completed within the next month, resulting in a Nasdaq filing under the ticker ATNF
• 180 Life Sciences’s founders are an experienced team of medical scientists who pioneered anti-inflammatory pharmaceuticals in the 1990s that are still in use today, generating billions in revenue
• The company’s own-IP clinical trials seek to resolve inflammation-related issues in conditions such as Dupuytren’s disease, frozen shoulder, arthritis, ulcerative colitis, liver fibrosis and nonalcoholic steatohepatitis
• Analysts forecast the anti-inflammatory therapeutics market will be worth $191.42 billion by 2027, growing at a CAGR of 3 percent

Clinical stage biotechnology company 180 Life Sciences Corp., whose scientific teams are led by drug developers renowned for producing some of the largest-selling pharmaceuticals to ever come to market, is accelerating toward a planned Nasdaq launch under a special purpose acquisition corporation (“SPAC”) that expects to rocket its research into novel anti-inflammatory therapies toward some stellar goals.

KBL Merger Corp. (NASDAQ: KBLM, NASDAQ: KBLMR, and NASDAQ: KBLMW), previously announced its SPAC merger plans with 180 Life Sciences to create a company to be trading under the ticker ATNF (https://nnw.fm/t7kM5), with closing anticipated by November (https://nnw.fm/4Q3aV). The company recently successfully closed bridge financing for working capital to advance its efforts to go public and develop its pipeline of important new pharmaceuticals.

Following U.S. Securities and Exchange Commission (“SEC”) approval of the company’s S4 registration statement earlier this month, the company organized a special meeting of stockholders for Oct. 26 regarding the business combination.

The clinical trial pipeline includes a Phase 2b/3 trial expected to result in data read-out in 2021 for therapies to fight early-stage Dupuytren’s disease, a condition in which one or more fingers become permanently bent in a flexed position.

Additional Phase 2 trials already  expected to be intiated by year-end or early 2021 include treatment of frozen shoulder, a common condition characterized by stiffness and severe pain in the shoulder joint.

Additonal planned  trails include an immune system suppression therapy to tackle Postoperative Cognitive Dysfunction (POCD), a condition manifesting as a long-lasting cognitive decline after surgery that is regarded as a major clinical problem with no clear cause or effective therapy at this point, although neuroinflammation is understood to play a critical role (https://nnw.fm/nRkgG).

These advanced trials involve the development of products to treat unmet medical needs through anti-TNF therapy, which seeks to block the activity of a substance in the body that can cause inflammation and lead to immune-system diseases.

The company also has begun preclinical studies looking at treatments for liver fibrosis and nonalcoholic steatohepatitis, inflammation-related pain, early arthritis and ulcerative colitis in ex-smokers, all with anticipated inflammatory system tie-ins.

“Our scientific team has unparalleled expertise and a proven track record of developing unique drugs that improved the lives of millions of people and created companies that were later sold for billions of dollars,” KBL Merger Corp. CEO Dr. Marlene Krauss stated in the June news release about the planned ATNF merger. “We have assembled this world-class team to build a unique, global biotechnology company dedicated to developing novel drugs in a cost-effective manner.”

Krauss has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACS, with the current venture marking her fourth SPAC in the healthcare space.

The medical scientist founders of 180 Life Sciences Krauss referred to are pioneers in the field of anti-inflammatory drugs, developing anti-TNF biologics and anti-integrin inhibitors in 1990s that are still on the market, spawning a new class of inflammation therapeutics.

For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://nnw.fm/180

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Gage expanding in Michigan, one of fastest-growing legal cannabis markets in United States
• Adult-use cannabis revenues in Michigan projected at $1 billion per year for 2021, surpassing $1.5 billion by 2023
• Gage currently operates 5 dispensaries, planning to open and operate 8-10 by the end of 2020, with 20+ expected to open by the end of 2021
• YTD revenue estimated at $30+ million, 157% increase from January to September 2020
• Gage planning Canadian listing for Q1 2021

Bruce Linton, a pioneer of the global cannabis industry and current executive chairman of Gage Cannabis Co., has set his sights on Michigan as the next big market for the rapidly growing cannabis industry in the United States. As a leading vertically integrated operator in the industry, Gage has already made significant headway into Michigan and is well-positioned to expand its footprint in record time.

“Michigan is one of the top cannabis markets in the U.S., and I am confident Gage is poised to continue building on its historical execution and fortifying its position as one of the top operators and brands in Michigan, as well as a name consumers look for across the United States,” said Linton in recent statements (https://nnw.fm/PriCl).

Since the recreational use of cannabis was legalized in 2018, Michigan has emerged as one of the fastest-growing legal cannabis markets in the United States in terms of consumption. State budget planners have projected recreational marijuana to be worth nearly $1 billion per year in fiscal 2021 with revenues eclipsing $1.5 billion by 2023 (https://.nnw.fm/9slXZ).

“The recreational industry, once fully implemented, will have a significant impact on Michigan’s economy, with hundreds of millions of dollars in tax revenue flowing into state and local governments,” said Michigan Cannabis Industry Association Director Robin Schnedier, who played an active role alongside both public and private interests to write the 2018 voter-passed legalization law.

“We’ve already begun to see waves of hiring by cannabis businesses looking to fill these good-paying jobs, which will have a major impact on communities as these workers have money to spend on goods and services at their local small businesses.”

Gage has already made significant investments in the state, including 8-10 medical or adult-use dispensaries currently open or in the works with at least 10 more planned for 2021. Besides its retail operations, Gage engages in cultivation and processing through 19 Class C cultivation licenses across four cultivation assets and three processing licenses with plans to further expand its cultivation facilities in the future.

Gage is committed to providing an enhanced cannabis experience starting with top-quality plants that are grown indoors, trimmed by hand and hung to dry. Besides flowers, the company’s brand also includes other unique product types that include edibles, hardware, vaping devices and concentrates.

Alongside its own in-house brands, Gage also operates with several strategic and brand partners on an exclusive basis such as Cookies – one of the most iconic cannabis lifestyle brands from Northern California. With delivery services offered within a one-hour radius of its dispensaries, the company’s footprint spans an estimated 90% of Michigan’s population. Dispensaries were among the businesses deemed “essential” during the recent COVID-19 shutdowns, allowing all Gage and Cookies locations to remain open while offering curbside pickup.

Despite the global economic recession, Gage posted impressive financial results for 2020 that included sales of $5.8 million in Q1 which bloomed to $11.9 million by Q2. Management expects the trend to continue with estimates for Q3 surpassing $13.1 million, representing an increase of over 150% in sales from January to September 2020. The company is currently planning a Canadian listing for the first quarter of 2021 (https://nnw.fm/6fNus) and has launched a Regulation A, Tier 2, equity financing.

For more information on Gage Cannabis Co., visit the company’s website at www.GageUSA.com.

To learn more about the company’s Regulation A financing, visit www.GageInvestors.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://nnw.fm/GAGE

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

When the pandemic began, many countries introduced guidelines to help curb the spread of the coronavirus. The most common of these included:

1.  Social distancing

2. Avoiding crowds; limiting the number of people in public places

3. Wearing a mask in public

However, these recommendations are based on decades-old scientific foundations that may not reflect the current state of knowledge. Consequently, several research groups have come together to develop a better and improved model of the spread of the disease’s infectious droplets. These researchers from the field of fluid dynamics have demonstrated that while it makes sense to maintain social distancing and wear a mask, this alone shouldn’t lull you into a false sense of security. Even with a mask on, these contagious droplets can be spread over several meters and remain in the air longer than researchers had previously thought.

Researchers from MIT (Boston), Clarkson University (Potsdam, New York), the Sorbonne (Paris), the University of Florida (Gainesville, Florida) and TU Wien (Vienna) were involved in the research project. The research project was published in the “International Journal of Multiphase Flow.”

Alfredo Soldati, a professor at TU Wien says that the globally accepted understanding of how droplets spread is based on measurements from the 1930s and ‘40s, but the measuring methods used during those periods weren’t as good as today’s technology. This led the researchers to suspect that small droplets couldn’t be reliably measured at that time.

The professor from the Institute of Fluid Mechanics and Heat Transfer goes on to add that in previous models, there was a difference between small and large droplets. The small droplets moved forward in an almost straight line while large droplets were pulled downwards by gravity. This, he says, makes the picture oversimplified, which only highlights the need to further adapt models to the latest research. This will help health experts better understand how the coronavirus spreads.

Soldati then adds that masks are useful because they stop large droplets. Maintaining a distance is also helpful. However, the results from the research study demonstrate that neither of these measures provide 100% protection.

The good news is that with the current simulations in progress and the new mathematical model, scientists can now calculate the concentrations of the contagious droplets at different times and distances. Soldati observes that up until now, coronavirus protection measures have been based on studies from the epidemiology and virology fields. He hopes that in the future, findings from the fluid mechanics field will also be included.

Many biomedical companies are currently engaged in developing treatments based on the latest research about different health conditions. One interesting company that you should follow is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). The company focuses on developing novel treatments for both primary and metastatic cancers, especially those affecting the brain and central nervous system. Berubicin, the company’s lead drug candidate, is poised to revolutionize how an aggressive form of brain cancer is treated.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered Incurable
• Production of Berubicin Begins in the U.S. and Europe
• Dual Manufacturing Facilities Engaged to Reduce Supply Chain Interruptions
• IND for Berubicin Could Be Filed by Year End

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an Investigational New Drug Application (“IND”) ready for its lead drug candidate, Berubicin, by the end of 2020. An approved IND would give the biotech company, which is developing treatments for primary and metastatic cancers of the brain and central nervous system, the green light to go ahead with clinical trials. In June, CNS Pharmaceuticals signed agreements with two manufacturing entities—one in the U.S., the other in Italy—for the production of Berubicin. Three months later, the manufacturing process has commenced, taking the company a step closer to getting an IND approved by the Food and Drug Administration (“FDA”). Berubicin has been specifically developed to target cancers of the brain, including the first targeted indication of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. To increase awareness of this destructive disease, a segment on “The Balancing Act, Behind the Mystery,” which airs on Lifetime TV, is focused on glioblastoma. The segment can be viewed here: (click for link).

The manufacturing of Berubicin marks an important milestone on the way to initiating clinical studies on GBM patients. CNS Pharmaceuticals has already completed synthesis of the Berubicin Active Pharmaceutical Ingredient (“API”), which has been shipped to Pii and BSP, manufacturing entities that will prepare an injectable form of Berubicin ready for clinical use. In June, CNSP hired USA-based Pharmaceutics International, Inc. (“Pii”) and Italian BSP Pharmaceuticals S.p.A. (“BSP”) to handle production. With this dual-track approach to manufacturing, the company reduces the risk of failing to meet its clinical timeline due to drug supply. Moreover, situating production in Europe as well as the U.S., provides localized availability of Berubicin for the upcoming Phase I pediatric and Phase II adult studies in Poland and the U.S. Phase II trial.

CNSP has also advanced its clinical agenda. The company recently hired Worldwide Clinical Trials as the contract research organization, Image Analysis Group (“IAG”) as the imaging partner, and Berry Consultants as a biostatistical advisor for its Phase 2 trial design. The company also added Dr. Patrick Wen, a renowned neuro-oncologist, to its Scientific Advisory Board. It has reiterated its expectation to initiate a U.S. Phase 2 trial for Berubicin in Q1 of 2021.

Glioblastoma is one of the most aggressive primary brain cancers in adults, with approximately 13,000 new patients diagnosed each year in the U.S.—the highest diagnosis rate of all malignant brain tumors. Yet, awareness of this pernicious malignancy is sorely lacking, although this may be changing after it struck down a number of well-known figures, including Senators Ted Kennedy and John McCain, as well as Beau Biden, son of Vice-President Joe Biden. However, press reports provide scant details of the affliction, an omission CNSP hopes the broadcast on the Lifetime TV show “The Balancing Act, Behind the Mystery” devoted to glioblastoma will correct. The segment relates the story of a glioblastoma patient, complemented by commentary on the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of the Scientific Advisory Board of CNS Pharmaceuticals. Aired on October 12, the segment will be re-broadcast on October 23, 2020.

For more information, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Last Saturday, medical cannabis dispensaries in Missouri made their first legal sales to qualified patients and caregivers. This comes less than two years after voters from Missouri approved a ballot measure to legalize medical cannabis.

N’Bliss Cannabis put up shop and opened doors in Manchester and Ellisville, two different St. Louis County locations. The director of the Missouri Department of Health and Senior Services, Dr. Randall Williams, stated in a press release that Missouri patients had always been the state’s north star as they worked towards implementing the state’s medical cannabis program. He added that they greatly appreciated how hard everyone had exerted themselves into ensuring that patients would be able to access a well-regulated and safe program.

Various officials have highlighted the speed at which they got the voter-approved marijuana program off the ground, stating that it was one of the fastest implementations of a medical cannabis program in the United States.

The director of the Section for Medical Marijuana Regulation, Lyndall Fraker, stated in a press release that a huge amount of work had been put in by the team and licensed facilities to get to the point they were at and that they heard from more facilities which were almost ready or ready for their commencement inspections. He added that they looked forward to seeing these facilities open their doors to serve both caregivers and patients.

The Missouri Medical Cannabis Trade Association was the first to announce on Friday that the launch of sales will happen the next day while the Springfield News-Leader was the first to report the good news of this announcement.

The state of Missouri has until now granted licenses to 192 dispensaries and expects that most if not all will have opened by the end of the year. The state also posted an interactive map that can be used to track the status of approved cannabis businesses.

For many months now, regulators have been immersed in appeals and lawsuits challenging the state’s licensing decisions, with revenues that should have been directed into veteran services being diverted and used to cover legal costs.

Furthermore, Missouri is not the only state that launched medical marijuana sales this past weekend. The state of Virginia also had its first medical cannabis dispensary grand opening on Saturday as well. Over in Maine, recreational sales of cannabis were introduced last week, roughly four years after voters had approved a legalization ballot measure.

Many companies are bringing a new twist to the cannabis space, and one interesting one to watch is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). They specialize in making perfectly balanced alkaline (pH of 8.8) water rich in trace minerals.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

In a bid to make the mining industry more sustainable, Codelco, Chile’s state copper miner and the world’s largest copper producer, is incorporating electro-mobility into its operations. However, major challenges lie ahead.

In a webcast, Codelco’s innovation management specialist, Gonzalo Ramirez, stated that greater electro-mobility adoptions inside the mines would be dependent on the availability of well-trained and informed people as well as the technological feasibility of the business. He mentioned that from a market perspective, the company needed to validate business models and lower battery prices while on the technological side, Codelco needed the massive use of equipment.

According to Ramirez, about 70% of carbon emissions inside a mining operation are produced by electric power consumption while the remaining 30% comes from the fuel used by the trucks.

In 2018, Codelco started testing electric vehicles inside its northern division. After this, the company introduced electric buses to transport workers at its Chuquicamata and El Teniente mines, in the Antofagasta and O’Higgins regions, respectively.

In addition, last year the company introduced hybrid equipment to be used for unloading, transportation and ore loading at El Teniente. Last week, Codelco and Engie,  an energy company, began the pilot phase of a new electric vehicle that the two companies had jointly developed.

During the webcast, Ramirez also talked about the incorporation of electric vehicles in the company’s underground operations. He noted that this strategic move was designed to decrease ventilation requirements, which were responsible for high energy costs.

With regard to Codelco’s electro-mobility business model, Ramirez stated that the EV batteries represented 30% to 40% of the cost of the vehicles. He mentioned that many companies are renting batteries and selling vehicles. In addition, Ramirez noted that the industry was adapting new business models that don’t require the purchase of batteries. This, he explained, is a disruption of how the company manages and consumes energy to drive its fleet.

The management specialist added that the human factor represented another challenge for electro-mobility in mining, explaining that it is vital to understand how to be drivers of change both as decision makers at the government level and as machine operators at the business level. The biggest challenge, he observed, was finding such capacity to drive change within the country.

Finally, Ramirez discussed the boost that local suppliers would receive as electro-mobility becomes widespread in mining operations, noting the need for supplier development to be local in terms of electro-mobility adoption.

One company worth watching in the mining sector is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). Energy Fuels focuses on producing uranium and vanadium, both of which are categorized by the U.S. federal government as critical minerals.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

• Cybin appoints health-care expert Doug Drysdale as new CEO.
• Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships.
• New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems.

Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://nnw.fm/wPyaa). Drysdale brings more than three decades of experience in the health-care sector and will continue to grow its IP portfolio.

“With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine. “We believe that his extensive health-care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”

Named an Ernst and Young Entrepreneur of the Year in 2012, Drysdale has served for 30 years in the health care sector. In 2014, he led the recapitalization of a NASDAQ-listed pharmaceutical company, raising $65 million as its corporate director. Following that move, Drysdale served as the company’s chairman and CEO. In that role, he focused on rebuilding the management team and board of directors; he also built a 220-person sales team. Under his continued leadership, the pharmaceutical company raised $465 million of capital; its enterprise value grew exponentially from $80 million to an estimated $800 million.

Before that, Drysdale headed M&A efforts at Actavis Group, leading 15 corporate acquisitions across three continents. Those efforts included a high-profile public hostile takeover attempt in Central Eastern Europe. During that same period, Drysdale raised approximately $3 billion of capital and managed lending syndicates, including over 25 banks, to fund its growth. In 2012, Watson Pharmaceuticals bought Actavis for €4.25 billion.

Drysdale led Norwich Pharmaceuticals into a new period of prosperity, eventually becoming CEO of its parent company, Alvogen Group. During his time as CEO, he grew Norwich’s two-product offering to more than 25 products, strengthened the company’s R&D capabilities and improved staffing efficiency by 25%.

“I am beyond excited to be joining the Cybin team,” said Drysdale. “I believe Cybin’s business model and talented management team uniquely positions the company to examine the efficacy of psychedelic-based therapies and delivery systems in treating mental illness and addiction disorders. I expect Cybin’s expanding development pipeline will allow the company to explore a cost-effective and timely array of health care alternatives.

“We will continue to grow our IP portfolio organically and shall be looking to add to our IP through accretive acquisitions,” he continued. “Research to date is showing positive indications for the potential use of psychedelic-based therapies as alternatives to current chronic depression medications and habit-forming opioids, for various treatment-resistant issues such as eating disorders, smoking cessation, PTSD, anxiety and depression. Mental illness and addiction have profoundly personal meanings for me and affect millions of people worldwide. I am proud to be in a position at Cybin to work to try to help countless patients and their families through the development of novel treatments.”

Cybin is an innovator in the stagnant pharmaceutical sector, where it aims to become the first life science company to bring psilocybin medicine targeting major depressive disorder to market.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

• Emerging Wellness Foods Brand Rritual Mushrooms Inc. is developing plant-based superfood products to lead out a fledgling market segment that has a high degree of promise as consumer interest in functional foods increases
• While the mushroom therapeutics subcategory of products is still new and developing, analysts researching the overall functional foods market expect the industry to grow at a CAGR of 7.9 percent to $275.77 billion between 2019 and 2025
• Rritual Mushrooms’ introductory product line draws on the reputations of the Chaga, Lion’s Mane and Reishi mushrooms as beneficial to overall wellness, combining them with herbal remedy adaptogens in powdered elixirs
• The three formulations are being rolled out this fall in 14-stick packs and in 250-gram tubs, as well as in a 14-day variety pack that includes all three elixirs

Researchers have found “enormous potential” for using mushrooms in functional foods, describing the fungal growth’s immunomodulating, anti-tumor, hypocholesterol and anti-bacterial properties as rife with opportunity for food products such as cereal and bread flours as well as cheeses and cheese-related products (https://nnw.fm/avg7h).

That potential is now being realized with the initial slate of products from lifestyle therapeutics innovator Rritual Mushrooms Inc., whose non-psychoactive wellness elixirs include a Chaga blend designed to augment immunity, a Lion’s Mane blend designed to support cognitive function and brain health, and a Reishi blend to boost the body’s ability to fight anxiety.

Rritual Mushrooms emerged in 2019 as a fledgling company targeting a fledgling industry segment in which no dominant brand has yet emerged to lead the functional foods subcategory. The company is building toward an IPO.

Despite the apparent novelty of the mushroom wellness movement, market analysts at Grand View Research, Inc. stated last year that they expect the overall functional foods market size to reach $275.77 billion in valuation by 2025, expanding at a CAGR of 7.9 percent between 2019 and 2025 (https://nnw.fm/48iA6), and mushroom food products stand to benefit as part of the trend.

The novel coronavirus pandemic that emerged this year is only expected to increase the demand for functional foods and other nutraceuticals as an infection-wary public seeks to utilize more immunity-boosting supplements in their diets.

In June, Rritual Mushrooms introduced Dr. Mike Hart as the company’s president who will help guide Rritual through plant-based wellness therapy developments (https://nnw.fm/38YgR). Hart operates his own family medicine clinic in London, Ontario, where he became the first physician in the locality to open a cannabis clinic in 2014. He continues to use wellness therapies to treat patients’ symptoms such as pain, inflammation, insomnia and depression.

“My belief is that mental fitness is a daily ritual, and Rritual’s product portfolio and approach completely supports my current research and values as a seasoned, plant-based practitioner,” Hart stated in the announcement of his appointment.

In general, mushrooms have twice the protein of asparagus, cabbage and other vegetables, and 12 times the protein found in oranges and apples. Edible mushroom are a good source of several vitamins, including thiamine (“B1”), riboflavin (“B2”), niacin, biotin and ascorbic acid (“C”) (https://nnw.fm/8oheF).

Rritual Mushroom’s product line pairs the Chaga mushroom with the adaptogen Eleuthero root, Lion’s Mane mushroom with the adaptogen Rhodiola root and the Reishi mushroom with the adaptogen Ashwagandha root for products full of bioactive polysaccharides that are helpful to the biome (https://nnw.fm/LFawP). Adaptogens are natural substances used in herbal remedies because they are thought to increase the resistance of organisms to biological stresses (https://nnw.fm/I3nTL).

The three formulations will be available in 14-stick packs and in 300-gram tubs during the fall, as well as a 14-day variety pack that includes all three elixirs. They will be marketed through Rritual’s website and the company’s Amazon store initially before expanding to other online and brick-and-mortar outlets.

For more information, visit the company’s website at www.WeAreRritual.com.

NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual

“Mental Fitness is a Daily Ritual“

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Researchers from University of Queensland recently discovered that the droplets of fat that exist inside our cells help our body’s defense system fight back against infections.

The international collaboration between researchers Professor Albert Pol from the University of Barcelona and Professor Robert Parton from UQ Institute for Molecular Bioscience discovered these fat droplets to be both a weapon and a food source against bacterial invaders.

Professor Parton stated that scientists had previously thought the bacteria merely used the lipid droplets as food but had found out that the fatty droplets were also involved in the battle between our cells and pathogens.

He added that the fat is part of the cell’s armory. The cells fire these lipid droplets at these foreign pathogens once they manufacture toxic proteins and package them into the lipid droplets. This, he says, is a way that cells are using to defend themselves; they use fats as a weapon, which provides new insights into other ways to fight body infections.

This comes at a time when researchers are working hard towards finding alternative ways of fighting infections, as antibiotic-resistant superbugs are on the rise. One potential alternative would be to increase the body’s natural defenses.

Professor Pol stated that when white blood cells called macrophages were infected, they observed that the lipid droplets moved to the part of the macrophage that housed the bacteria.

They noted that how white blood cells used energy was also affected by the bacterial infection. Pol added that the lipid droplets could be used as an alternative source of fuel for mitochondria when other nutrients weren’t sufficient. During an infection, the lipid droplets moved away from the mitochondria and attacked the bacteria instead, which altered the cells’ metabolism.

Professor Parton, who is a cell biologist, was inspired to carry on with this research after the phenomenon that was observed in fruit flies.

He remarked that many had thought the lipid droplets to be blobs of fat which were only useful for energy storage. However, now that researchers have observed them acting as metabolic switches in the cell, defending the body against infection and more, entire scientific conferences of researchers have been dedicated to researching more about them.

He then added that the next step in their research was to discover how the lipid droplets targeted the bacteria. That way, they could not only understand the body’s natural defenses but also develop new therapies that would be reliant on antibiotics to fight infections that were drug-resistant.

The biomedical space is bringing to light lots of novel discoveries and therapies based on those discoveries. One interesting company to watch in this regard is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). They focus on developing products to address any unmet needs of treating different conditions yet clinical evidence of efficacy for helpful interventions exists.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Recent study reports CAGR of 9.7% in precision medicine space.
• Predictive Oncology focused on use of data, artificial intelligence to develop personalized cancer therapies.
• One of POAI’s primary projects is building multi-omic predictive models of tumor drug response

A recent study of the global precision medicine market indicates a bright future for the industry, especially for U.S.-based companies focusing on cancer research, such as Predictive Oncology Inc. (NASDAQ: POAI). The study reported a CAGR of 9.7% in the sector, with North America dominating the market and oncology expected to hold the highest market.

“Precision medicine, a combination of molecular biology techniques and systems biology, is an emerging approach for disease treatment and prevention,” the Mordor Intelligence study stated. “The market growth for this approach is gaining momentum, as it takes into account individual variability in genes, environment and lifestyle for each person, while developing drugs and vaccines.”

The report goes on to note that North America currently dominates the precision medicine market and is “expected to continue its stronghold for a few more years.” The United States holds the largest market share on the continent, at least in part due to the Precision Medicine Initiative (“PMI”), launched by former President Barack Obama.

This initiative was designed to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into everyday clinical practice. The PMI enjoys widespread support, including ongoing efforts through the Department of Veteran’s Affairs (“VA”), the Food and Drug Administration (“FDA”), the Office of the National Coordinator for Health IT and the Office for Civil Rights.

The study also reports that “precision medicine applications are primarily directed toward better treatment against oncological diseases, with an estimated more than 30% market dominance over other segments. . . . The high support from the government through funding and rapid growth of genomic analysis are expected to augment the growth of the precision medicine market at a fast rate, over the forecast period.”

This analysis bodes well for Predictive Oncology, an industry leader focused on the use of data and artificial intelligence (“AI”) to develop predictive models of tumor drug response and outcome, which can be used to help oncologists individualize current cancer therapies for the patients as well as help researchers find new cancer therapies. The Mordor report noted that key factors propelling the growth of the precision medicine market include increasing online collaborative forums, increasing efforts to characterize genes and advancements in cancer biology — all of which POAI is involved in.

“The fundamental concept of precision medicine is to understand the genetic makeup and difference at a population level, and further at an individual level, in order to customize a drug that targets a particular gene type,” the report observed. “Hence, sequencing or characterizing genes is the most important method to gain information about genes and their possible mutations.”

One of POAI’s primary projects, conducted through its subsidiary Helomics, is building multi-omic predictive models of tumor drug response and outcome using a its unique proprietary TumorSpace knowledge base of 150,000 tumor drug response profiles gathered from over 15 years of clinical testing. Using artificial intelligence, the company is leveraging this data to build predictive models of tumor drug response. These models offer researchers in pharma, biopharma and diagnostic companies actionable information that drives the development of new precision therapies, companion diagnostics, biomarkers and helps design better-targeted trials — all with the end goal of helping patients diagnosed with cancer.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated, patient-derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information about Predictive Oncology, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A new study reveals that the lockdowns imposed in various countries to curb the spread of COVID-19 at the beginning of the pandemic around Europe and in China improved air quality. This was seen in regions that suffered from high mortality rates caused by air pollution.

Scientists from the University of Notre Dame recently published research in the Lancet Planetary Health journal that showed the decline in particulate matter concentrations in Europe and China. During the lockdown that was imposed in Europe between February 21 and May 17, particulate matter concentrations reduced by 17.1% while in China, the concentrations reduced by 29.7% in the lockdown period of February 1 and March 31.

These concentrations are small airborne particles that come from different combustion-related sources, such as wildfires, transportation, industrial emissions and chemical reactions of pollutants in the atmosphere.

The corresponding author of the study, Paola Crippa, says that the lockdowns, which have led to forced low-emission scenarios due to restrictions, show that very polluted areas can improve immensely in reducing air pollution if strict measures are put in place.

Air pollution may not sound as a real threat but is actually considered to be the leading environmental cause of death. So, it is in fact, a real and credible threat. The World Health Organization released findings in 2016 that showed the number of premature deaths caused by air pollution worldwide to be 4.2 million. The Southeast Asian and Western Pacific regions were the most affected by this.

Long-term exposure to areas with high air pollution can be fatal to humans and their health, with many succumbing to death due to lung cancer, chronic obstructive pulmonary diseases, stroke and ischemic heart disease.

The research team led by the author, who is also an assistant professor in the Department of Civil and Environmental Engineering and Earth Sciences at the University of Notre Dame, estimated that in China from February to March, about 24,200 deaths associated with particulate matter were prevented. They also noted that the improvement in air quality was recorded across China because of the lockdown measures that were imposed and extended. In Europe, the study estimates that 2,190 premature deaths were averted during the lockdown period.

This study highlights the need for stricter control policies to be developed and implemented in order to reduce air pollution and achieve effective air quality improvements. The policies may also include subsidies to electric vehicles as well as the adoption of strict emission limitations for industries.

Many biomed companies have set out to save thousands if not millions of lives. One interesting firm you should watch is CNS Pharmaceuticals Inc. (NASDAQ: CNSP). They specialize in developing novel remedies for metastatic and primary cancers, especially those affecting the central nervous system and the brain.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Round of financing led by Bruce Linton, executive chairman of Gage Cannabis and cannabis industry pioneer
• Reg A+ equity financing offers chance to invest in exclusive cultivator, processor, and retailer of world-leading cannabis brands
• First step in Gage’s journey to becoming publicly traded company

Gage Cannabis Co., the leading high-quality craft cannabis brand and operator in Michigan, has launched a Regulation A, Tier 2, equity financing. The pre-IPO round of financing is being led by Bruce Linton, executive chairman of Gage Cannabis, a founder and former CEO and chairman of Canopy Growth Corp.

“We wanted to provide investors with the opportunity to invest in a growing and dominant cannabis operation before an official IPO process,” said Linton. “Michigan is one of the top cannabis markets in the U.S., and I am confident Gage is poised to continue building on its historical execution and fortifying its position as one of the top operators and brands in Michigan, as well as a name consumers look for across the United States.”

Linton transformed Canopy Growth Corp. from a concept into one of the most recognizable and valuable cannabis companies in the world. A passionate entrepreneur, he has decades of experience in a variety of industries, creating unprecedented long-term shareholder value. As the first and lead investor in the offering, his unwavering support and confidence in Gage Cannabis is clear.

The round of financing consists of up to 28,571,400 shares of subordinate voting shares, available for $1.75 per share. The shares are being offered pursuant to Regulation A of Section 3(b) of the Securities, as amended, for Tier 2 offerings, by management on a “best-efforts” basis directly to purchasers who satisfy the requirements set forth in Regulation A.

For investors, the pre-IPO opportunity to invest in the exclusive cultivator and retailer of several world-leading cannabis brands can’t be ignored. The company’s exclusive brands include Cookies, Lemonnade, Runtz, Grandiflora, SLANG Worldwide, and OG Raskal; Gage also has its own proprietary brand portfolio, distributed in Michigan.

The leaders at Gage Cannabis are focused on becoming the retailer of choice among adult-use and medical-cannabis consumers. Initially, Gage has opened five dispensaries, with plans to open three more locations by the end of 2020; the company intends to have more than 20 operating stores by the end of next year. So far this year, Gage has reported $31 million in sales, with that number only expected to increase in the coming months.

“We’re excited to invite public investors to join alongside industry juggernauts, like Bruce Linton, and provide them with the opportunity to participate in our future success,” said Fabian Monaco, President of Gage Cannabis. “We have strategically acquired a portfolio of high-quality operating assets and brands in the rapidly growing Michigan market and developed a reputation for providing consumers with access to craft cannabis in elevated retail environments. This is a great first step in our journey to becoming a publicly traded company, and we’re excited to continue to build on our strong foundation while delivering long-term shareholder value.”

Gage Cannabis Co. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries).

The Company encourages all interested investors to visit GageInvestors.com for a link to the Offering Circular and to learn how to invest in the Offering. Financing information is also available by calling toll free at 1-844-606-0809 or locally at 1-616-504-6060

For more information, visit the company’s website at www.GageInvestors.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis Co. are available in the company’s newsroom at https://nnw.fm/GAGE

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Researchers at Brock and McMaster universities have developed a prototype for a tool which will allow patients to use a blood sample to test for the presence of cancer biomarkers. This technology has specifically been designed to assess the levels of prostate-specific antigens (“PSA”), but it can be tweaked to test for other cancers as well.

According to the researchers, the device operates in just the same way that hand-held glucose monitors work. A patient just mixes a tiny drop of blood in a vial which contains a reactive fluid, and then a sample from this mixture is placed on a strip which is inserted into the portable device for analysis.

In a couple of minutes, the reader would provide results showing the extent to which the cancer antigens are present in the blood sample tested.

Leyla Solemani, one of the lead researchers on this project based at McMaster’s University and also the chair of Miniaturized Biomedical Devices in Canada, stated that their work was a big step towards the delivery of personalized medical care to patients, in exactly the same way as what biomed companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are attempting to deliver customized medical care around the world.

The prototype takes diagnostics and monitoring away from hospital settings and brings it into the homes of patients. This makes cancer prognosis and diagnosis more accessible, especially for populations that aren’t close to the healthcare centers with the needed testing facilities.

The developers say that their device will need to undergo broader tests before the necessary regulatory approvals can be secured to pave the way for the commercial production and widespread use of the diagnostic tool.

However, the research team is optimistic that their device will pass all the regulatory requirements and it will be used to save lives and revolutionize clinical outcomes for the patients who are most in need of testing services.

The ability to gather real-time data about the progress of a cancer patient would help doctors and other allied professionals to design appropriate treatment protocols while making timely adjustments to those treatment plans as the condition of the patient evolves. This would be preferable to responding long after the condition of the patient has changed and the change is discovered when the patient comes to a health facility for their scheduled follow-up sessions. The era of lab-based tests could soon come to an end if such hand-held testing kits become widely available.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

A study led by researchers at the University of Texas Southwestern Medical Center suggests that native chemicals (endocannabinoids), which are similar to the cannabinoids produced by marijuana plants, have the potential to inhibit the virulence of intestinal bacteria.

The team found that our endocannabinoids can shut down the genes which are required for some intestinal pathogens to colonize and cause disease. This study sheds some light on why marijuana has for long been used to alleviate different gastrointestinal infections.

The researchers sought to establish whether endocannabinoids can lessen one’s susceptibility to the different pathogenic bacteria which cause gastrointestinal infections.

To answer this question, the team genetically altered a group of mice so that the rodents could produce higher levels of an endocannabinoid called 2-AG (2-arachidonoyl-glycerol). The genetically modified mice were then injected with a bacterial pathogen called citrobacter rodentium. This pathogen is responsible for attacking the colon and causing extreme inflammation and diarrhea. Unmodified mice were also injected with this pathogen.

The researchers then observed that the unmodified mice displayed severe gastrointestinal distress characterized by colon inflammation, severe diarrhea and signs of infection. Their fecal matter also had high levels of citrobacter rodentium.

However, the genetically modified mice not only recovered days quicker than their unmodified cohorts, but they also had lower inflammation markers in their colons, and their symptoms of infection were mild.

The researchers then genetically modified the mice which hadn’t initially mutated and when these were injected with the pathogens, they exhibited mild symptoms and recovered quickly from the infection.

Vanessa Sperandio, PhD, the leader of this study, revealed that the endocannabinoid 2-AG also protected the mice from E-coli and salmonella typhimurium.

When the team treated mammalian cells in a petri dish with a compound which blocks 2-AG, those cells had a heightened susceptibility to the gastrointestinal pathogens with which the mice had been injected.

The research authors observe that their findings could explain why cannabis compounds or their synthetic versions have beneficial effects on inflammatory bowel issues. They believe that with such findings, it could soon be possible to use the body’s own compounds or those derived from plants to treat infections in a way that hasn’t been attempted before.

It is noteworthy that this research was supported by five grants from the National Institutes for Health (“NIH”). These findings will undoubtedly open the door of possibilities to lots of biomedical companies. One biomedical company whose work is worthy looking into is Predictive Oncology (NASDAQ: POAI). They focus on delivering precision or personalized cancer medicine using the power of artificial intelligence and data.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Despite the concept of electric vehicles (“EVs”) being decades old, the industry is relatively new. Consumers interested in reducing their carbon footprint and switching green are positively bursting with questions about the fledgling industry and how it works. To help interested parties get a clearer picture of the EV industry, consumer group Which? Has given expert answers to five of the most nagging EV questions most consumers have.

Are electric cars really that green? You’d be forgiven for thinking EVs produce zero emissions, but we’re still a ways off from that technology. But don’t let that discourage you from going green: research has found that although electric cars are not entirely green, they don’t pollute the environment as much as petrol and diesel-powered vehicles. According to an analysis by BloombergNEF, carbon emissions produced by electric vehicles charged with non-renewable power are still 40% lower than the outputs of cars with combustion engines.

How much do I have to worry about range? Not as much, apparently. While drivers who went green early had to fork over a lot more for an expensive EV with more range, improvements in battery technology have resulted in much more affordable models with extended ranges. Instead of paying a whopping $103,000 on an expensive Tesla so you can travel more than 200 miles on a single charge, you could opt for more affordable models like the Hyundai Kona or the Kia e-Niro that will offer you similar range.

Are electric cars more reliable? Compared to traditional vehicles, electric vehicles have far fewer moving parts, and the assumption is that this makes them more reliable and less likely to break down. However, a 2019 poll found that petrol and hybrid car owners had fewer problems to report than EV owners. Just over one in four owners of EVs under three years old reported an issue. But despite the higher overall fault rate, EV owners are still among the most satisfied car owners.

Are electric cars more practical to run? If you have a home charger and are confident you can charge your EV somewhere off the road, then yes, it would be practical to own an EV. However, if you live in flats or have to rely on the famously unreliable public charging systems, you may find yourself questioning the choice to go green. Unless you drive a Tesla, which has its own charging network, and you cannot install a home charger, you may have to rely on several apps, websites, or a radio-frequency identification (“RFID”) card to gain access to public charging networks.

Are EVs less expensive to own than traditional vehicles? Overall, studies have shown that EVs are cheaper to own and maintain over their lifetime than petrol and diesel-powered vehicles. However, as the initial costs can be quite high, plenty of prospective buyers are unable to go green. Improvements in battery technology over the next five years will make EVs much more affordable but at the moment, customers have to rely on government programs and grants that make buying relatively expensive EVs possible.

Several companies are picking interest in the electric vehicle space with the view to addressing some of the little kinks that still exist in this vehicle segment. One such company that is interesting to follow is Net Element (NASDAQ: NETE). The global financial solutions company is set to complete a reverse merger with an electric vehicle maker.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

If you are planning to buy some mining industry stocks, it is wise to do your due diligence so that you don’t fall for clever marketing hype geared at luring unsuspecting investors into pouring money into a risky company. Here are some specific issues to investigate with respect to a company’s mineral exploration activities.

Geological Potential

A mining company needs to base its exploration activities on sound science rather than on speculation. It is therefore vital for you to confirm that the company you wish to invest in invests in exploration and can provide proof of geological indicators for the prospects that they are pursuing. If the jurisdictions in which they are exploring show geological potential, put a check on that specific box and evaluate the other issues on your checklist.

The Legal Environment

With competent management and proper laws, a mining company’s exploration activities can yield the expected results while the same cannot be said for a jurisdiction with unclear or inconsistently implemented laws.

An appropriate legal framework is like a well-paved highway. As you select which mining stocks to buy, find a company whose operations are based in jurisdictions with well-laid permitting processes, a history of laws that support mining activity and relatively low bureaucratic requirements.

The Political Environment

In some jurisdictions, policies can suddenly and drastically change based on who wins an election. For example, when a leader who is against mining gets elected as president, he or she can quickly nationalize all mining operations to the detriment of the affected mining companies.

It is therefore wise to sieve out those mining companies which don’t operate in jurisdictions where there is rule of law and government policies are stable. Otherwise, buying stocks in a company operating in jurisdictions rife with corruption or where the political system is volatile means you are taking on way too much risk.

Infrastructure and Labor

It is desirable that mining exploration takes place in an environment which has suitable infrastructure, such as gridlines, road networks and trained labor to execute the exploration activities. If such infrastructure is lacking, a forward-looking mine can make plans to be the catalyst that spurs development in the jurisdictions where it operates. This can be a great way to win the support of the local communities.

When you identify a mining company whose activities check all the boxes above, you will have moved a step closer to ensuring that your money is safe and that you will get a return on your investment. A company of interest that you can look at while studying the factors above in operation is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). They specialize in the production of uranium and vanadium, both of which are categorized by the U.S. federal government as critical minerals.

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.